Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
11 Settembre 2023 - 10:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease and other diseases driven by
abnormally elevated aldosterone, today announced that its Chief
Executive Officer Jon Congleton, and Chief Financial Officer and
Chief Business Officer, Adam Levy, will participate in a fireside
chat at the Cantor Fitzgerald Global Healthcare Conference in New
York on Thursday, September 28, 2023 at 9:10 a.m. ET.
Cantor Fitzgerald Global Healthcare
Conference:
Date: |
Thursday,
September 28, 2023 |
Time: |
9:10 a.m. ET |
Webcast: |
A live webcast of the fireside chat can be accessed under
“News and Events” on the Investor Relations section of the
Mineralys website at www.mineralystx.com. A replay of the webcast
will be available on the Company’s website for approximately 90
days. |
About MineralysMineralys Therapeutics is a
clinical-stage biopharmaceutical company focused on developing
medicines to target hypertension, chronic kidney disease and other
diseases driven by abnormally elevated aldosterone. Its initial
product candidate, lorundrostat, is a proprietary, orally
administered, highly selective aldosterone synthase inhibitor that
Mineralys Therapeutics is developing for cardiorenal conditions
affected by abnormally elevated aldosterone, including hypertension
and CKD. Mineralys is based in Radnor, Pennsylvania, and was
founded by Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Grafico Azioni Mineralys Therapeutics (NASDAQ:MLYS)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mineralys Therapeutics (NASDAQ:MLYS)
Storico
Da Lug 2023 a Lug 2024